Harbour BioMed raises €67.4M to treat coronavirus & cancer
Harbour BioMed, a Cambridge, MA- Rotterdam, The Netherlands and Suzhou, China-based global, clinical-stage biopharmaceutical company, closed a $75 million (€67.4 million approx) Series B+ round of financing.